✦ LIBER ✦

A randomized controlled double blind study of zuclopenthixol acetate compared to haloperidol in acute psychosis

✍ Scribed by S. Brook; M. Berk; S. Selemani; J. Kolloori; I. Nzo

Publisher: John Wiley and Sons
Year: 1998
Tongue: English
Weight: 88 KB
Volume: 13
Category: Article
ISSN: 0885-6222
DOI: 10.1002/(sici)1099-1077(199801)13:1<17::aid-hup937>3.0.co;2-g

No coin nor oath required. For personal study only.

✦ Synopsis

This study is a double blind randomized controlled trial comparing zuclopenthixol acetate to haloperidol administered parenterally initially and followed by oral medication for 28 days in the treatment of acute psychosis. The sample included 44 patients with schizophrenia, schizophreniform disorder and substance-induced psychotic disorder who required acute neuroleptic treatment. The patients were assessed using the Brief Psychiatric Rating Scale (BPRS), Clinical Global Improvement Scale (CGI) and the Simpson Angus Scale (SAS). While patients in both groups improved on all outcome measures, there was no signi®cant dierences between the two agents in terms of either ecacy or tolerability.

📜 SIMILAR VOLUMES

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 2 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre

A multicenter, randomized, double-blind

A multicenter, randomized, double-blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: Results of a phase III clinical trial

✍ Daniel L. Rubin; Terry S. Desser; Richard Semelka; Jeffrey Brown; Hanh V. Nghiem 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB 👁 2 views